GlassScriptPhysician profile
Jayant Kumar
NPI 1558451039
$12,257.89
in general payments reported to CMS, 2019-2025
44 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $373 · 2021: $1,678 · 2022: $1,684 · 2023: $4,695 · 2024: $1,959 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818 · Consulting Fee: $2,400 · Travel and Lodging: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,817.90 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $1,617.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $3,761.87 | 2021-2025 | Korsuva, Velphoro |
| Calliditas Therapeutics US INC. | $1,370.88 | 2023-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $845.61 | 2019-2024 | Farxiga, Lokelma |
| Nxstage Medical, INC. | $823.37 | 2021-2025 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $820.74 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $669.66 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $636.46 | 2021-2025 | |
| Daiichi Sankyo INC. | $491.19 | 2019-2024 | Injectafer |
| Horizon Therapeutics Plc | $394.44 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $357.21 | 2019-2023 | Jynarque |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $316.57 | 2020-2021 | |
| Akebia Therapeutics INC | $187.19 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $168.40 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.75 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $151.18 | 2022-2025 | Benlysta |
Show all 38 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayant Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.